Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs Markman B; Dienstmann R; Tabernero JOncotarget 2010[Nov]; 1 (7): 530-543It is well established that the PI3K pathway plays a central role in various cellular processes that can contribute to the malignant phenotype. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, agents targeting upstream receptor tyrosine kinases are best studied and have achieved greatest clinical success. Further downstream, despite efficacy in certain tumor types, the rapalogs have been somewhat disappointing in the clinic. Novel inhibitors of PI3K, Akt, and mTORC1 and 2 are now passing through early phase clinical trials. It is hoped that these agents will circumvent some of the shortcomings of the rapalogs and lead to meaningful benefits for cancer patients.|*Phosphoinositide-3 Kinase Inhibitors[MESH]|Animals[MESH]|Humans[MESH]|Models, Biological[MESH]|Molecular Targeted Therapy/methods/*trends[MESH]|Neoplasms/*drug therapy/metabolism[MESH]|Phosphatidylinositol 3-Kinases/metabolism[MESH]|Protein Kinase Inhibitors/*therapeutic use[MESH]|Proto-Oncogene Proteins c-akt/*antagonists & inhibitors/metabolism[MESH]|Signal Transduction/drug effects[MESH]|TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism[MESH] |